Anap­tys­Bio drops an­oth­er in­di­ca­tion for lead drug af­ter it fails a sec­ond PhII study in 12 months

Anap­tys­Bio’s lead drug has failed an­oth­er mid-stage study, lead­ing to its dis­con­tin­u­a­tion in ac­ne.

The biotech re­vealed Mon­day af­ter­noon that its an­ti-IL-36R an­ti­body im­si­dolimab did not show ef­fi­ca­cy over place­bo in ei­ther pri­ma­ry or sec­ondary end­points for its Phase II tri­al. Though Anap­tys­Bio did not re­veal p-val­ues, pa­tients on place­bo saw greater nu­mer­i­cal re­duc­tions of fa­cial ac­ne than ei­ther of the low- or high-dose im­si­dolimab co­horts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER